List of Excipients in Branded Drug LYSTEDA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ferring Pharmaceuticals Inc	LYSTEDA	tranexamic acid	55566-2110	CELLULOSE, MICROCRYSTALLINE
Ferring Pharmaceuticals Inc	LYSTEDA	tranexamic acid	55566-2110	HYPROMELLOSE
Ferring Pharmaceuticals Inc	LYSTEDA	tranexamic acid	55566-2110	MAGNESIUM STEARATE
Ferring Pharmaceuticals Inc	LYSTEDA	tranexamic acid	55566-2110	POVIDONE
Ferring Pharmaceuticals Inc	LYSTEDA	tranexamic acid	55566-2110	SILICON DIOXIDE
Ferring Pharmaceuticals Inc	LYSTEDA	tranexamic acid	55566-2110	STARCH, CORN
Ferring Pharmaceuticals Inc	LYSTEDA	tranexamic acid	55566-2110	STEARIC ACID

Lysteda Excipient Strategy and Commercial Opportunities for Tranexamic Acid Tablets

Last updated: August 26, 2026

Lysteda is a 650 mg immediate-release oral tablet containing tranexamic acid for the short-term treatment of cyclic heavy menstrual bleeding. Its commercial opportunity is concentrated in generic substitution, differentiated oral formulations, excipient optimization, contract manufacturing, and international expansion. The principal barriers are bioequivalence, tablet size, dissolution control, supply reliability, and the need to preserve the established safety and dosing profile.

What is Lysteda and how is it regulated?

Lysteda contains tranexamic acid, a synthetic lysine analogue that inhibits fibrinolysis. The FDA approved Lysteda tablets in 2009 for cyclic heavy menstrual bleeding in women with normal renal function. The labeled regimen is 1,300 mg orally twice daily for a maximum of five days during monthly menstruation. [1]

Attribute	Lysteda profile
Active ingredient	Tranexamic acid
Strength	650 mg
Dosage form	Immediate-release film-coated tablet
FDA application	NDA 022430
Indication	Cyclic heavy menstrual bleeding
Typical labeled dose	1,300 mg twice daily for up to five days
Administration	Oral
Regulatory pathway for competitors	ANDA, with waiver or bridging strategy where applicable
Biosimilar exposure	None; tranexamic acid is a small molecule
Primary commercial reference	Lysteda 650 mg tablets

Lysteda did not receive new chemical entity exclusivity because tranexamic acid was an established active ingredient. Its principal FDA marketing exclusivity was the three-year exclusivity associated with approval of a new use or formulation, which expired in 2012. [2]

What is the FDA regulatory status of Lysteda?

Lysteda remains an FDA-approved prescription product, while generic tranexamic acid tablets have entered the U.S. market. Generic competition relies on substantial-equivalence and bioequivalence requirements rather than clinical redevelopment of tranexamic acid for the same indication. The FDA Drugs@FDA database and Orange Book remain the controlling sources for the current NDA, ANDA, patent, exclusivity, and therapeutic-equivalence status. [2,3]

What excipients are used in Lysteda tablets?

The Lysteda product labeling identifies a conventional direct-compression or dry-granulation excipient system. The inactive ingredients include microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, and stearic acid. The film coating contains hypromellose, titanium dioxide, talc, and polyethylene glycol. [1]

Formulation function	Lysteda excipient class	Commercial role
Diluent and tablet body	Microcrystalline cellulose	Supports tablet mass, compactability, and mechanical strength
Binder	Povidone	Improves granule or tablet cohesion
Superdisintegrant	Crospovidone	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Stearic acid	Reduces ejection friction
Film former	Hypromellose	Creates the protective tablet coating
Opacifier and color component	Titanium dioxide	Controls appearance and light protection
Anti-tacking agent	Talc	Improves coating-process performance
Plasticizer	Polyethylene glycol	Improves coating flexibility

This platform is commercially attractive because the excipients are widely available, compendial materials with established oral-tablet use. A generic manufacturer does not need to copy every inactive ingredient, but the finished product must meet relevant quality, performance, safety, and bioequivalence requirements. FDA inactive-ingredient databases can support excipient precedent analysis, although they do not replace product-specific formulation and regulatory assessment. [4]

How can excipient selection improve a generic Lysteda product?

The highest-value excipient work is likely to involve process robustness rather than a radically new formulation. Tranexamic acid tablets require a high active load, making tablet weight, hardness, friability, disintegration, and swallowability important development variables.

Tablet size and swallowability

A 650 mg active dose is substantial. Patients commonly take two tablets per dose, creating a four-tablet daily burden under the labeled regimen. A manufacturer that reduces tablet volume without compromising dissolution could improve patient acceptability and manufacturing economics.

Potential approaches include:

• Higher-functionality microcrystalline cellulose grades.
• Co-processed excipients that improve compactability.
• Granulation to increase bulk density.
• Lubricant optimization to reduce over-lubrication.
• A thinner film coat with controlled weight gain.
• A smaller, higher-density tablet geometry.

A smaller tablet is commercially useful, but any change must preserve dissolution and tablet mechanical properties. Tranexamic acid is highly water soluble, so the main formulation risk may be mechanical integrity and manufacturability rather than slow drug release.

Disintegration and dissolution

Crospovidone is a logical platform excipient because it supports rapid tablet disintegration without adding a large amount of water-soluble polymer. Development teams can screen crospovidone grade, particle size, intragranular versus extragranular placement, and concentration.

A formulation that disintegrates too rapidly can create friability or powdering problems. A formulation that is too hard or over-lubricated can delay dissolution. The target is a robust design space that remains compliant across:

• Active-material particle-size variation.
• Compression-force changes.
• Humidity exposure.
• Long-term storage.
• Manufacturing-scale transfer.
• Multiple excipient suppliers.

Coating optimization

The coating is a practical differentiation point. A generic manufacturer can evaluate:

• Lower coating weight gain.
• A titanium-dioxide-free or lower-titanium-dioxide coating where permitted.
• Alternative color systems.
• Polyethylene-glycol level and molecular weight.
• Moisture-barrier performance.
• Reduced coating time and lower energy consumption.

Color changes can create product-identification and medication-error concerns. A visually distinct generic may be acceptable, but the imprint, shape, color, and packaging must support safe substitution and comply with FDA requirements.

What formulation patents protect Lysteda?

Lysteda's original commercial differentiation came from the oral tablet formulation and use of tranexamic acid for heavy menstrual bleeding, rather than from exclusivity in the active ingredient itself. The relevant intellectual-property categories include:

1. Use patents covering tranexamic acid for heavy menstrual bleeding.
2. Formulation patents covering oral tablet composition or performance.
3. Manufacturing patents covering granulation, compression, coating, or stability.
4. Patent claims directed to dosing schedules or patient populations.
5. Regulatory exclusivity associated with the approved NDA.

Most early Lysteda-related rights were filed well before or around the 2009 approval period. Standard U.S. patent terms generally run 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory rules. [5]

The commercial implication is that legacy Lysteda exclusivity is substantially less important than it was during the first generic-entry period. A current applicant should still review the FDA Orange Book, USPTO Patent Center, issued patent records, litigation dockets, and any pediatric or regulatory exclusivity entries before relying on an expiration conclusion. [3,5]

What is the Orange Book status of Lysteda?

The Orange Book determines whether FDA-listed patents and exclusivity entries affect an ANDA applicant. A current review should distinguish among:

• Listed patents associated with NDA 022430.
• Expired patents.
• Unexpired patents with remaining regulatory significance.
• Use codes that may support a Paragraph IV certification.
• Patent disputes that no longer block approval.
• Therapeutic-equivalence ratings for approved generic products.

For Lysteda, the commercial pathway is generally an ANDA strategy based on the reference product's safety and efficacy findings. The primary legal exposure is a Paragraph IV challenge if a relevant patent remains listed and unexpired. [3,6]

When does Lysteda lose exclusivity and what generic entry risks exist?

Lysteda's three-year FDA exclusivity expired in 2012. Generic entry risk therefore depends mainly on patent status, ANDA approval, manufacturing capacity, and market economics rather than on remaining FDA exclusivity.

Barrier	Current commercial relevance
NCE exclusivity	Not applicable to this established active ingredient
Three-year approval exclusivity	Expired
Orange Book patents	Must be reviewed for current, unexpired listings
Paragraph IV litigation	Possible only if a relevant unexpired listed patent remains
Biosimilar pathway	Not relevant
Bioequivalence	Core technical requirement
Supply chain	Important because tranexamic acid is a high-volume, low-cost active
Retail pricing	Likely subject to generic erosion
Differentiation	Requires formulation, packaging, supply, or channel advantages

Which companies are challenging Lysteda?

Generic tranexamic acid tablets have been marketed by multiple manufacturers over time, including companies operating through ANDA approvals, authorized generic arrangements, or distributor-label relationships. The identity of active challengers can change as ANDAs are approved, acquired, withdrawn, or launched.

A reliable competitive review should use the FDA Orange Book and Drugs@FDA rather than rely on historical litigation summaries. Paragraph IV activity should be assessed against the specific patent list in force at the time of filing. [2,3]

What commercial opportunities exist for Lysteda excipient suppliers?

The strongest opportunity is not a novel excipient claim. It is supply and performance optimization around a mature, high-volume tablet platform.

High-value excipient opportunities

Opportunity	Commercial rationale
Co-processed direct-compression excipient	Reduces process steps and improves tablet robustness
High-density cellulose grade	Supports smaller tablets
Functional crospovidone	Improves disintegration at high drug load
Low-moisture excipient system	Supports stability and lower packaging cost
Titanium-dioxide-free coating	Addresses customer and regional formulation preferences
Ready-to-use film coating	Reduces color-matching and process-development work
Multi-source excipient qualification	Reduces supply interruption risk
Continuous manufacturing excipient package	Supports process intensification
Low-dust powder grades	Improves occupational and plant handling performance

Excipient suppliers can create value by providing comparative data on compactability, ejection force, disintegration, dissolution, friability, and stability. Regulatory support packages, change-control documentation, and dual-sourcing plans can be as important as the material itself.

Is an extended-release or combination product commercially attractive?

Extended-release tranexamic acid could reduce peak exposure or dosing frequency, but it would not be a straightforward generic Lysteda opportunity. It would likely require a new formulation development program, clinical or comparative pharmacokinetic work, and a separate regulatory strategy.

Combination products with hormonal contraceptives or iron are commercially conceivable but carry higher regulatory and safety complexity. A fixed-dose combination would need to address differing dosing schedules, contraindications, patient populations, and labeling requirements.

The more practical near-term opportunity is an immediate-release tablet with improved size, packaging, swallowability, or supply economics.

What manufacturing and intellectual-property barriers affect commercial entry?

Manufacturing barriers

The active ingredient represents most of the tablet mass, so small changes in active-material properties can affect compression and dissolution. Key controls include:

• Particle-size distribution.
• Bulk and tapped density.
• Moisture content.
• Flowability.
• Polymorphic or crystalline-state consistency.
• Blend uniformity.
• Compression force.
• Ejection force.
• Coating uniformity.
• Packaging moisture protection.

A manufacturer should qualify at least two sources of critical excipients and assess their impact on the finished product. The commercial risk is often a failed scale-up or post-approval change rather than an inability to formulate the tablet initially.

IP barriers

A new excipient strategy may create patentable subject matter if it produces a measurable technical result, such as:

• A defined tablet-size reduction at equivalent mechanical strength.
• A specific dissolution profile under challenging conditions.
• Improved stability under high humidity.
• A manufacturing process with lower defect rates.
• A coating system that reduces processing time.
• A composition that avoids a still-active formulation claim.

Routine substitution of one compendial excipient for another is less likely to produce strong composition-of-matter protection. Patent strength improves when the formulation includes narrow quantitative ranges tied to reproducible performance data.

How strong is the Lysteda patent estate compared with other branded drugs?

Lysteda has a weaker long-term exclusivity profile than newer products protected by composition-of-matter patents, complex delivery systems, biologic manufacturing claims, or extensive device patents. Tranexamic acid is an old small molecule, and biosimilar-style barriers do not apply.

Product characteristic	Lysteda	New chemical entity	Biologic
Active-ingredient patent moat	Low	Often high	Usually high
Formulation importance	Moderate	Moderate to high	High
Bioequivalence pathway	ANDA	ANDA after patent expiry	Biosimilar or interchangeable pathway
Biosimilar risk	None	None	Material
Manufacturing complexity	Moderate	Variable	High
Generic price erosion risk	High	High after loss of exclusivity	Often slower
Excipient differentiation value	Moderate	Moderate	High in some products

What revenue exposure and launch scenarios should investors assess?

Lysteda revenue is exposed to generic substitution, payer preferences, wholesaler stocking, and the availability of low-cost tranexamic acid products. Public revenue estimates should be treated carefully because brand and generic sales may be reported differently across companies and channels.

Three launch scenarios are commercially relevant:

1. A conventional ANDA launch with the reference-strength 650 mg tablet and limited differentiation.
2. A supply-led launch offering reliable availability, dual sourcing, and competitive contract pricing.
3. A differentiated launch using a smaller tablet, improved coating, optimized packaging, or a targeted international formulation.

The first scenario is the easiest to execute but faces the highest price pressure. The second can win institutional and distributor business. The third may support better margins but requires stronger development evidence and may create additional regulatory review.

Key Takeaways

• Lysteda is a 650 mg immediate-release tranexamic acid tablet approved for cyclic heavy menstrual bleeding.
• Its three-year FDA exclusivity expired in 2012; current entry analysis depends on Orange Book patents and ANDA status.
• The formulation uses conventional excipients, including microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, stearic acid, hypromellose, titanium dioxide, talc, and polyethylene glycol.
• The best excipient opportunities involve tablet density, swallowability, disintegration, coating efficiency, moisture control, and supply resilience.
• Biosimilar risk is irrelevant because tranexamic acid is a small molecule.
• Generic competition is likely to produce substantial price erosion, making manufacturing cost and supply reliability central to commercial success.
• Strong new patent positions would require measurable technical advantages rather than routine excipient substitution.

FAQs

Can a generic Lysteda tablet use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product satisfies FDA requirements for safety, quality, performance, labeling, and bioequivalence.

Is tranexamic acid a biologic or biosimilar product?

No. Tranexamic acid is a synthetic small molecule. Competitors use the generic drug approval pathway, not the biosimilar pathway.

Can a smaller Lysteda tablet be patented?

Potentially. Patentability would depend on the formulation's novelty, non-obviousness, and demonstrated technical advantages, such as improved compactability or equivalent dissolution at reduced tablet volume.

Does Lysteda have an OTC commercial opportunity?

Lysteda is an FDA-approved prescription product. An OTC switch would require a separate FDA regulatory program, including consumer-label comprehension and self-selection evidence.

Which excipient is most important for a generic Lysteda tablet?

No single excipient determines product performance. Microcrystalline cellulose, crospovidone, and the lubricant system are likely to have the greatest influence on compression, disintegration, and dissolution during development.

References

1. U.S. Food and Drug Administration. (2023). Lysteda (tranexamic acid) tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Lysteda, NDA 022430. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.

5. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension resources. USPTO.

6. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity: Questions and answers. FDA.